The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Stanford scientists have developed broadly neutralizing antibodies against sarbecoviruses , including SARS-CoV-2 related Clade 1b, SARS-CoV related Clade 1a and Clade 3 viruses, paving the way for future vaccines and therapeutics.
Researchers at Stanford have developed a CRISPR-based system to degrade viral RNA, with potential applications as both an anti-viral therapeutic and a prophylactic treatment against influenza, SARS-CoV-2, and other viruses.
Researchers at Stanford have developed a microparticle-based vaccine that in a single shot enables enhanced activation of CD8+ and/or CD4+ T cells to fight against infectious diseases and cancer.